Stock comparison
Catalyst Pharmaceuticals
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CPRX
Catalyst Pharmaceuticals
Market cap
$3.83B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.06B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CPRX | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 69C | 75B | IDXX |
| Benjamin Graham | 75B | 80A | IDXX |
| Philip Fisher | 87C | 75B | CPRX |
| Peter Lynch | 65B | 71B | IDXX |
| Joel Greenblatt | 42D | 83C | IDXX |
| Charlie Munger | 78B | 87A | IDXX |
| Terry Smith | 78B | 84A | IDXX |
Side-by-side metrics
| Metric | CPRX | IDXX |
|---|---|---|
| Market cap | $3.83B | $44.06B |
| P/E (TTM) | 17.3x | 39.0x |
| EV/EBIT | 11.9x | 31.6x |
| ROIC (TTM) | 19.67% | 40.66% |
| Gross margin | 82.32% | 62.05% |
| Net margin | 37.08% | 24.63% |
| Revenue CAGR 5y | 43.0% | 7.56% |
| EPS CAGR 5y | 46.49% | 10.79% |
| Debt / Equity | 0.0x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CPRX leads on
- Debt / Equity0.0xvs 0.7x+100%
- Revenue CAGR 5y43.0%vs 7.56%+82%
- EPS CAGR 5y46.49%vs 10.79%+77%
- EV/EBIT11.9xvs 31.6x+62%
IDXX leads on
- Market cap$44.06Bvs $3.83B+91%
- ROIC (TTM)40.66%vs 19.67%+52%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.